{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:59:06Z","timestamp":1790643546555,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Johnson & Johnson"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"DOI":"10.1007\/s12325-026-03801-2","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T07:49:26Z","timestamp":1790581766000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Perspectives on Living with Relapsed\/Refractory Multiple Myeloma and Multidisciplinary Care from a Patient, Nurse Practitioner, Dietitian, and a Patient Advocate"],"prefix":"10.1007","author":[{"given":"Becky","family":"Bosley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Wlodkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Catamero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Meredith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"issue":"12","key":"3801_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00757-8","volume":"12","author":"S Goldman-Mazur","year":"2022","unstructured":"Goldman-Mazur S, Visram A, Rajkumar SV, et al. Second- and third-line treatment strategies in multiple myeloma: a referral-center experience. Blood Cancer J. 2022;12(12):164.","journal-title":"Blood Cancer J"},{"issue":"17","key":"3801_CR2","doi-asserted-by":"publisher","first-page":"5866","DOI":"10.1002\/cam4.4137","volume":"10","author":"S Kumar","year":"2011","unstructured":"Kumar S, Williamson M, Ogbu U, Surinach A, Arndorfer S, Hong WJ. Front-line treatment patterns in multiple myeloma: an analysis of U.S.-based electronic health records from 2011 to 2019. Cancer Med. 2011;10(17):5866\u201377.","journal-title":"Cancer Med"},{"issue":"5","key":"3801_CR3","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1182\/blood.2019000722","volume":"134","author":"A Chari","year":"2019","unstructured":"Chari A, Martinez-Lopez J, Mateos MV, et al. Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma. Blood. 2019;134(5):421\u201331.","journal-title":"Blood"},{"key":"3801_CR4","doi-asserted-by":"publisher","first-page":"117822421986823","DOI":"10.1177\/1178224219868235","volume":"13","author":"SA Bird","year":"2019","unstructured":"Bird SA, Boyd K. Multiple myeloma: an overview of management. Palliat Care Soc Pract. 2019;13:1178224219868235.","journal-title":"Palliat Care Soc Pract"},{"issue":"S1","key":"3801_CR5","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.5045\/br.2020.S008","volume":"55","author":"JH Lee","year":"2020","unstructured":"Lee JH, Kim SH. Treatment of relapsed and refractory multiple myeloma. Blood Res. 2020;55(S1):S43\u201353.","journal-title":"Blood Res"},{"issue":"1","key":"3801_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clml.2019.09.621","volume":"20","author":"J Mikhael","year":"2020","unstructured":"Mikhael J. Treatment options for triple-class refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2020;20(1):1\u20137.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"14","key":"3801_CR7","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1200\/JCO.18.02096","volume":"37","author":"J Mikhael","year":"2019","unstructured":"Mikhael J, Ismaila N, Cheung MC, et al. Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline. J Clin Oncol. 2019;37(14):1228\u201363.","journal-title":"J Clin Oncol"},{"issue":"1","key":"3801_CR8","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/bjh.14193","volume":"175","author":"MS Raab","year":"2016","unstructured":"Raab MS, Cavo M, Delforge M, et al. Multiple myeloma: practice patterns across Europe. Br J Haematol. 2016;175(1):66\u201376.","journal-title":"Br J Haematol"},{"key":"3801_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2021.100808","volume":"49","author":"K Ramasamy","year":"2021","unstructured":"Ramasamy K, Gay F, Weisel K, Zweegman S, Mateos MV, Richardson P. Improving outcomes for patients with relapsed multiple myeloma: challenges and considerations of current and emerging treatment options. Blood Rev. 2021;49:100808.","journal-title":"Blood Rev"},{"key":"3801_CR10","unstructured":"TALVEY (talquetamab-tgvs). Prescribing information. Horsham, PA: Janssen Biotech, Inc; 2023."},{"key":"3801_CR11","doi-asserted-by":"crossref","unstructured":"Chari A, Oriol A, Krishnan A, et al., editors. Efficacy and safety of less frequent\/lower intensity dosing of talquetamab in patients with relapsed\/refractory multiple myeloma: results from the phase\u00a01\/2 MonumenTAL-1 study. Presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition; 2023 December 9\u201312; San Diego, CA.","DOI":"10.1182\/blood-2023-181228"},{"issue":"4","key":"3801_CR12","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625\u201338.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"3801_CR13","doi-asserted-by":"publisher","first-page":"6330","DOI":"10.3390\/curroncol30070467","volume":"30","author":"M Markouli","year":"2023","unstructured":"Markouli M, Ullah F, Unlu S, et al. Toxicity profile of chimeric antigen receptor T-cell and bispecific antibody therapies in multiple myeloma: pathogenesis, prevention and management. Curr Oncol. 2023;30(7):6330\u201352.","journal-title":"Curr Oncol"},{"issue":"5","key":"3801_CR14","doi-asserted-by":"publisher","first-page":"e205","DOI":"10.1016\/S1470-2045(24)00043-3","volume":"25","author":"P Rodriguez-Otero","year":"2024","unstructured":"Rodriguez-Otero P, Usmani S, Cohen AD, et al. International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma. Lancet Oncol. 2024;25(5):e205\u201316.","journal-title":"Lancet Oncol"},{"issue":"19","key":"3801_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.71276","volume":"14","author":"N van de Donk","year":"2025","unstructured":"van de Donk N, Chari A, Martin T, et al. Characterization and management of cytokine release syndrome from the monumenTAL-1 study of talquetamab in patients with relapsed\/refractory multiple myeloma. Cancer Med. 2025;14(19):e71276.","journal-title":"Cancer Med"},{"issue":"10","key":"3801_CR16","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.clml.2024.05.003","volume":"24","author":"A Chari","year":"2024","unstructured":"Chari A, Krishnan A, Rasche L, et al. Clinical management of patients with relapsed\/refractory multiple myeloma treated with talquetamab. Clin Lymphoma Myeloma Leuk. 2024;24(10):665-93 e14.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"3801_CR17","doi-asserted-by":"crossref","unstructured":"Catamero D, Purcell K, Ray C, et al., editors. Practical management of patients with relapsed\/refractory multiple myeloma receiving talquetamab, a GPRC5DxCD3 bispecific antibody: experience in MonumenTAL-1. Presented at the 20th International Myeloma Society (IMS) Annual Meeting Nurse Symposium; 2023 September 27\u201330; Athens, Greece.","DOI":"10.1016\/S2152-2650(23)02116-X"},{"key":"3801_CR18","doi-asserted-by":"publisher","unstructured":"Sandahl T, Rattu MA, Jiang G, et al. Management of patients with relapsed\/refractory multiple myeloma treated with talquetamab: highlights from pharmacists\u2019 perspectives. J Adv Pract Oncol. 2025:1\u201316. https:\/\/doi.org\/10.6004\/jadpro.2025.16.7.15.","DOI":"10.6004\/jadpro.2025.16.7.15"},{"key":"3801_CR19","doi-asserted-by":"publisher","first-page":"743","DOI":"10.2147\/CMAR.S441550","volume":"17","author":"KC Miller","year":"2025","unstructured":"Miller KC, Hamadeh I, Tan CR. Perspectives on talquetamab and its utility in the treatment of multiple myeloma: safety, efficacy and place in therapy. Cancer Manag Res. 2025;17:743\u201356.","journal-title":"Cancer Manag Res"},{"key":"3801_CR20","doi-asserted-by":"crossref","unstructured":"Popat R, van de Donk NWCJ, Faiman B, et al. editors. Utility and sensitivity of WETT-SA53 to measure dysgeusia associated with talquetamab, a GPRC5DxCD3 bispecific antibody, in relapsed\/refractory multiple myeloma: preliminary data from the TALISMAN study. Presented by R Popat at the 67th Amercian Society of Hematology (ASH) Annual Meeting; 2025 December 6\u20139; Orlando, FL, USA.","DOI":"10.3324\/haematol.2026.s2.14053"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03801-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03801-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03801-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:05:31Z","timestamp":1790640331000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03801-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":20,"alternative-id":["3801"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03801-2","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"assertion":[{"value":"15 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Donna Catamero has served on a speakers\u2019 bureau and has been on a steering committee for Johnson & Johnson. Becky Bosley, Isabelle Wlodkowski, and Sarah Meredith have no conflicts of interest to disclose.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}}]}}